ECTRIMS 2023 | Advances in targeting the complement system for multiple sclerosis

Francesca Gilli, PhD, Dartmouth College, Hanover, NH, discusses ongoing efforts to enhance therapeutic approaches for neurodegenerative diseases by targeting the complement system. Specifically, the focus is on inhibiting the classical complement pathway, with C1q as the main target. The aim is to develop patient-friendly, non-invasive strategies that can effectively reach the central nervous system. Through the inhibition of C1q or alternative approaches, the goal is to slow down or halt disease progression. Ongoing research is aimed at studying the mechanisms behind this inhibition and exploring the best treatment options overall. This interview took place at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress 2023 in Milan, Italy.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.